Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

NCT05982093 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HER2-negative Breast Cancer
Hormone Receptor Positive Tumor
Premenopausal Breast Cancer

Interventions

DRUG: Elacestrant
DRUG: Triptorelin
DRUG: Tamoxifen 20 mg

Sponsor

SOLTI Breast Cancer Research Group